Jivi

Drug Overview

In the specialized field of hematology, managing chronic bleeding disorders requires a combination of advanced science and dedicated patient care. Jivi is a modern prescription medication classified as an Antihemophilic Factor (PEGylated). It is specifically engineered to treat Hemophilia A, a condition where the blood does not clot properly due to a lack of a vital protein called Factor VIII.

As a BIOLOGIC therapy, Jivi is not a chemical drug but a protein produced through recombinant DNA technology. It serves as a TARGETED THERAPY because it identifies and replaces the specific missing component in the coagulation cascade. Jivi is distinguished by its “extended half-life” design, meaning it stays active in the bloodstream longer than traditional clotting factors.

• Generic Name: Antihemophilic Factor (Recombinant), PEGylated-aucl
• US Brand Names: Jivi
• Route of Administration: Intravenous (IV) Injection
• FDA Approval Status: FDA-approved for the treatment of previously treated adults and adolescents (12 years of age and older) with Hemophilia A.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Jivi works, it is helpful to visualize the blood’s “coagulation cascade.” Think of this as a row of dominoes. When you get a cut, the first domino falls, triggering a chain reaction of proteins that eventually creates a solid clot to stop the bleeding. In patients with Hemophilia A, the “domino” known as Factor VIII is missing. Without it, the chain reaction stops, and the body cannot form a stable clot, leading to prolonged bleeding.

Jivi acts as a high-tech replacement for this missing Factor VIII. Once injected into the vein, Jivi enters the bloodstream and waits for the signal that a bleed has occurred. When activated, it works with other proteins (specifically Factor IXa) to activate Factor X, which is a critical step in producing thrombin. Thrombin then converts liquid fibrinogen into solid fibrin strands, which act like a net to trap blood cells and form a plug.

At the molecular level, Jivi is unique because of a process called PEGylation. Scientists attach a molecule called polyethylene glycol (PEG) to the Factor VIII protein. This PEG molecule acts as a protective shield. It disguises the protein from the body’s natural “clearing” systems in the liver and kidneys. By hiding the protein from these receptors, Jivi remains in the circulation much longer than non-PEGylated factors. This allows patients to maintain protective levels of Factor VIII for longer periods, effectively reducing the frequency of infusions needed for prophylaxis.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Jivi is the management of Hemophilia A (congenital Factor VIII deficiency). Within the realm of hematology, Jivi is used specifically for:

• On-demand treatment: Controlling and stopping active bleeding episodes.
• Perioperative management: Controlling bleeding during and after surgical procedures.
• Routine prophylaxis: Regular, scheduled infusions to prevent or reduce the frequency of bleeding episodes.

Jivi is specifically approved for patients who have been “previously treated,” meaning they have already received other Factor VIII products in the past. It is indicated for those 12 years of age and older.

Other Approved & Off-Label Uses

• Routine Prophylaxis for Joint Health: Used to reduce the risk of spontaneous joint bleeds, which can lead to permanent joint damage (hemophilic arthropathy).
• Home Administration: Approved for self-administration by patients or caregivers following proper training by a hematologist or hemophilia treatment center.
• Note: Jivi is not indicated for the treatment of von Willebrand disease.

Dosage and Administration Protocols

Dosing for Jivi is highly personalized. It is calculated based on the patient’s body weight and their specific bleeding patterns. Because it has an extended half-life, many patients can achieve protection with fewer infusions per week compared to standard products.

Important Adjustments:

• Maximum Infusion Rate: Jivi should be administered at a rate that is comfortable for the patient, usually not exceeding 2.5 mL per minute.
• Pediatric Patients: Jivi is not approved for children under the age of 12.
• Renal/Hepatic Insufficiency: No specific dose adjustments are required for patients with kidney or liver impairment, as the protein is processed differently than traditional drugs, though overall health must be monitored.
• Clinical Response: Doses may be increased if the patient does not achieve the target Factor VIII levels or if bleeding is not controlled.

Clinical Efficacy and Research Results

The effectiveness of Jivi was established through the PROTECT VIII clinical trial program. This research focused on how well the drug could prevent bleeds and how long it remained active in the body.

The study showed that Jivi provided a significant reduction in the “Annualized Bleeding Rate” (ABR). In patients who switched to a twice-weekly prophylaxis regimen, the median ABR was reduced to approximately 1.9. Remarkably, for those on the once-weekly regimen of 60 IU/kg, approximately 74 percent of patients were able to stay on that schedule for the entire six-month study period without experiencing significant bleeds.

Further data indicated that for on-demand treatment, over 90 percent of bleeding episodes were successfully controlled with only one or two infusions. In surgical settings, surgeons rated the blood-stopping ability of Jivi as “excellent” or “good” in 100 percent of the cases studied. This evidence confirms that Jivi is a highly reliable TARGETED THERAPY for the long-term management of Hemophilia A.

Safety Profile and Side Effects

Black Box Warning

There is currently no FDA “Black Box Warning” for Jivi. However, patients and healthcare providers must be vigilant for severe allergic reactions and the development of inhibitors.

Common side effects (>10%)

• Headache
• Cough
• Nausea
• Fever (Pyrexia)
• Injection site reactions (redness or itching where the needle was inserted)

Serious adverse events

• Hypersensitivity (Allergic) Reactions: In rare cases, patients may experience chest tightness, dizziness, or swelling of the face.
• Inhibitor Development: This is a major concern in hematology. The body’s immune system may recognize the drug as foreign and develop “inhibitors” (antibodies) that neutralize the Factor VIII, making the treatment ineffective.
• Thromboembolism: While rare in hemophilia patients, over-correcting the clotting factors could theoretically lead to unwanted blood clots.

Management Strategies

If a side effect occurs during an infusion, the process should be stopped immediately. For mild reactions, antihistamines may be used. If an inhibitor is suspected (indicated by the drug not working as well as it used to), the hematologist must perform a “Bethesda assay” to measure the level of antibodies. In the case of severe allergic reactions (anaphylaxis), emergency medical intervention with epinephrine is required.

Research Areas

Current research is exploring the long-term impact of PEGylation. Because the PEG molecule is not easily broken down by the body, active clinical trials are monitoring its long-term storage in tissues over decades. Furthermore, researchers are looking at how Jivi might be used in “Immune Tolerance Induction” (ITI) for patients who have developed inhibitors. There is also ongoing research into novel delivery systems, such as subcutaneous (under the skin) injections, to replace the need for intravenous access in the future.

Disclaimer: The research mentioned regarding the long-term accumulation of PEG in tissues and its use in Immune Tolerance Induction (ITI) is an active area of post-marketing surveillance and clinical study. While PEGylation is widely used in medicine, the specific long-term metabolic pathway of 60 kDa PEG in the choroid plexus or other tissues over decades is a focus of ongoing academic inquiry and is not yet part of standard clinical practice or validated as a risk factor in 2026.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Baseline Factor VIII Activity: To determine the severity of the hemophilia.
• Bethesda Assay: To screen for pre-existing inhibitors.
• CBC (Complete Blood Count): To check baseline blood cell levels.
• Organ Function: Standard tests for liver and kidney function (AST, ALT, Creatinine).

Precautions during treatment

• Inhibitor Monitoring: Routine blood tests are necessary to ensure the body is not fighting against the medication.
• Infusion Log: Patients should keep a detailed record of every dose, the lot number, and any bleeding symptoms.
• Vigilance: Be aware of the signs of a bleed, such as tingling, warmth, or pain in the joints.

“Do’s and Don’ts” List

• DO store Jivi in its original carton to protect it from light.
• DO refrigerate Jivi, but you may keep it at room temperature (up to 77 degrees Fahrenheit) for a single period of up to 6 months.
• DO use the provided sterile administration set for each infusion.
• DON’T use Jivi if you are allergic to hamster proteins, as it is produced in hamster cells.
• DON’T shake the vial when mixing, as this can damage the BIOLOGIC protein. Gently swirl instead.
• DON’T skip scheduled prophylaxis doses, even if you feel healthy.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Always consult with a specialized hematologist before beginning any new treatment for Hemophilia A. If you experience an emergency bleed or a severe allergic reaction, seek immediate medical attention.